How Long Does JUVÉDERM® Last Compared With Botox?

JUVÉDERM® can last from about 6 months to 2 years, depending on the product and treated area. FDA approval studies and official US product pages report cheek-smoothness improvement with SKINVIVE™ by JUVÉDERM® through 6 months; lips, under-eyes, chin, and jawline results up to 1 year; JUVÉDERM® VOLLURE® XC in nasolabial folds up to 18 months; and JUVÉDERM® VOLUMA® XC in the cheeks up to 2 years with optimal treatment. BOTOX® Cosmetic lasts approximately 3 to 4 months for glabellar lines, according to its US prescribing information.

Which symptoms after a JUVÉDERM® injection require emergency care?

> Get immediate medical help during or shortly after filler injection for unusual pain; any vision change; white, gray, or blue skin near the injection site; or stroke signs such as sudden trouble speaking, facial droop, weakness, numbness, difficulty walking, severe headache, dizziness, or confusion. These are the FDA’s patient instructions. Sudden vision or stroke symptoms warrant a 911 call.

Vascular occlusion is uncommon and time-sensitive. A 2021 JAMA Dermatology cohort covering 1.7 million syringes reported one occlusion per 6,410 1-mL syringe injections with needles and one per 40,882 with cannulas. Those are filler-wide rates from 370 board-certified dermatologists, rather than JUVÉDERM®-only rates. In the FDA’s 270-patient VOLUMA® XC cheek study, there were no vascular occlusions, yet the approval summary still classifies the complication as a rare risk.

I once reduced a red-flag card to pain and vision changes, leaving out skin color changes and stroke signs. That edit cost a full correction cycle and, worse, created false reassurance for a caller whose symptom was absent from the shortened list. Since that correction, I place the complete FDA symptom set before the first duration table.

How long does JUVÉDERM® last in each facial area?

The useful comparison pairs the exact product with its FDA-approved job. “JUVÉDERM®” names a collection of gels with different formulations, injection depths, study endpoints, and treatment goals.

| FDA-approved treatment goal | Product | Duration reported with optimal treatment | Named source | | --- | --- | ---: | --- | | Improve cheek skin smoothness | SKINVIVE™ by JUVÉDERM® | Through 6 months | FDA SSED P110033/S059 | | Correct age-related cheek volume loss | JUVÉDERM® VOLUMA® XC | Up to 2 years | FDA SSED P110033 and official cheek page | | Improve moderate to severe temple hollowing | JUVÉDERM® VOLUMA® XC | More than 1 year | Official JUVÉDERM® temple page | | Augment the chin profile | JUVÉDERM® VOLUMA® XC | Up to 1 year | Official JUVÉDERM® chin page | | Improve moderate to severe loss of jawline definition | JUVÉDERM® VOLUX® XC | Up to 1 year | Official JUVÉDERM® jawline page | | Correct moderate to severe facial folds, including nasolabial folds | JUVÉDERM® VOLLURE® XC; JUVÉDERM® Ultra Plus XC | Up to 18 months; up to 1 year | FDA VOLLURE® XC SSED and official smile-lines page | | Augment lips; correct perioral lines with VOLBELLA® XC | JUVÉDERM® VOLBELLA® XC; JUVÉDERM® Ultra XC | Up to 1 year | Official JUVÉDERM® lip page | | Improve under-eye hollows | JUVÉDERM® VOLBELLA® XC | Up to 1 year | FDA SSED P110033/S053 and official under-eye page |

SKINVIVE™ sits at the short end because its approved goal is cheek skin smoothness through intradermal microdroplet injections. VOLUMA® XC performs the separate job of replacing cheek volume through deep subcutaneous or supraperiosteal injection. Treating those two “cheek fillers” as interchangeable would erase the distinction that matters.

Around 2021, I stopped approving a single lifespan for the whole brand. I had thought one clean range helped readers. The same VOLUMA® XC label now supports up to 2 years in cheeks, up to 1 year in the chin, and more than 1 year in temples. That is why the table separates three VOLUMA® XC indications instead of assigning the product one date.

What do the 18-month and 2-year claims actually measure?

The 18-month figure comes from the FDA pivotal study for VOLLURE® XC in nasolabial folds. The 123 participants received VOLLURE® XC in one fold and a control filler in the other. The median initial-plus-touch-up volume was 1.7 mL per fold. FDA-scheduled assessments occurred at months 1, 3, 6, 9, 12, 15, and 18 after the last treatment.

At month 18, 59.4% of evaluated VOLLURE® XC-treated folds remained at least one grade better than baseline, and 67.8% of subjects assessed for satisfaction scored it from 7 to 10 on an 11-point scale. Different denominators appear because some folds were treated again or corrected for asymmetry and then counted as nonresponders, while some participants did not reach every assessment. “Up to 18 months” is a supported endpoint; it is not the date on which every result disappears.

For VOLUMA® XC cheeks, the FDA study followed treated patients at months 1, 3, and 6, then quarterly through month 24. The median volume was 6.6 mL across the midface regions studied, rather than 6.6 mL in one small spot. At month 24, 67.1% of the 167 evaluated patients still showed at least a one-point improvement on the Mid-Face Volume Deficit Scale. The patient-rated Global Aesthetic Improvement Scale responder rate was 93% at month 6.

Those injection volumes describe study populations. They are not shopping quantities or recommended personal doses. The FDA’s VOLUMA® review found device-related adverse events more often in patients receiving more than 9 mL and in patients older than 60, which makes “How many syringes?” a clinical planning question rather than a shortcut to longer duration.

How long does JUVÉDERM® take to settle?

JUVÉDERM® adds visible volume immediately, but swelling, tenderness, firmness, bruising, or lumps can temporarily distort the first look. Official US product pages report that common reactions generally lasted 14 days or less for VOLLURE® XC and Ultra XC, up to 30 days for VOLBELLA® XC, and about 2 to 4 weeks for VOLUMA® XC in cheeks and chin.

The FDA studies commonly placed an optional touch-up about 30 days after the initial injection. That protocol makes the one-month review a more defensible decision point than a verdict on day two. Earlier evaluation is appropriate when pain, color change, worsening swelling, infection signs, a firm nodule, or asymmetry concerns appear; the emergency symptoms listed above should never wait for a routine follow-up.

I cannot personally vouch for how one patient’s tissue will settle or how one injector’s technique will affect the result. I can vouch for the wording boundary: the 14-day, 30-day, and 2-to-4-week figures are reported reaction windows, while an individual clearance date requires the treating clinician’s examination.

Does JUVÉDERM® last longer than Botox, and does that make it the better choice?

JUVÉDERM® often has the longer labeled duration. VOLUMA® XC cheek results can last up to 2 years, VOLLURE® XC fold results up to 18 months, and several JUVÉDERM® treatments up to 1 year. The BOTOX® Cosmetic prescribing information gives an approximate 3-to-4-month effect for glabellar lines and says dosing more often than every 3 months has not been clinically evaluated.

Duration cannot decide between them because the mechanisms and targets differ. JUVÉDERM® is a hyaluronic-acid gel placed into tissue to add volume or, for SKINVIVE™, improve cheek skin smoothness. BOTOX® Cosmetic inhibits acetylcholine release at the neuromuscular junction, reducing activity in selected muscles. A dynamic frown line and a volume-depleted cheek are different treatment problems even when they occupy the same face.

My position is to choose the anatomical job first and compare duration second. A shorter-acting neuromodulator can be the more appropriate option for muscle-driven lines. A filler can address a fold, hollow, lip, chin, cheek, temple, or jawline that muscle relaxation will not rebuild. A qualified care team can also decide whether separate areas call for both products.

When should JUVÉDERM® be touched up or repeated?

A touch-up completes the initial correction after early swelling settles; repeat treatment restores a result that has faded. In the FDA studies, optional touch-ups occurred about 30 days after initial treatment for VOLUMA® XC, VOLLURE® XC, VOLBELLA® XC under-eyes, and SKINVIVE™. SKINVIVE™ repeat treatment was offered at 6 months.

The VOLLURE® XC fold trial permitted repeat treatment after month 12 or 15 when the fold had returned to baseline, and all remaining participants became eligible at month 18. Its median repeat volume was 0.6 mL per fold, about one-third of the 1.7 mL median used for initial treatment plus touch-up.

The strongest argument for planned maintenance is valid. Treating before complete fade may preserve continuity, and the VOLLURE® trial used less gel at repeat treatment. The study still tied earlier retreatment to an observed return to baseline. I would carry that logic into patient guidance by setting a review window from the product study, then letting appearance, symptoms, goals, and the clinician’s exam determine whether another injection is due.

How common are ordinary JUVÉDERM® side effects?

Common injection-site reactions are frequent, while serious complications were uncommon in the approval studies. In the FDA VOLUMA® XC cheek study, 98.1% of 265 diary completers recorded at least one treatment-site response. Among all 270 treated patients, 32.6% had a device- or injection-related adverse event after initial treatment and touch-up; two patients, or 0.7%, had device-related serious adverse events, and all resolved with treatment.

Definitions matter. The VOLUMA® study counted a diary reaction continuing beyond 30 days as an adverse event. In the FDA VOLBELLA® XC under-eye study, treating investigators recorded treatment-related adverse events in 9.5% of 105 initially treated participants; bruising and swelling each occurred in 3.8%, with no treatment-related serious adverse events. Different areas, protocols, and event rules make those percentages unsuitable for a head-to-head safety ranking.

What else do patients ask about JUVÉDERM® duration?

Does JUVÉDERM® last longer than Botox?

Usually, yes by labeled duration. BOTOX® Cosmetic lasts approximately 3 to 4 months for glabellar lines, while JUVÉDERM® results range from 6 months for SKINVIVE™ cheek smoothness to 2 years for VOLUMA® XC cheeks. They solve different problems. Botox reduces muscle activity; JUVÉDERM® adds hyaluronic-acid volume or improves cheek skin smoothness.

What is the riskiest facial area for filler injections?

The glabella between the eyebrows had the highest mean severity of vascular occlusions in the 2021 JAMA Dermatology cohort; lips and nasolabial folds had the most occlusions. The FDA warns that unintended intravascular injection anywhere can cause skin necrosis, vision loss, blindness, or stroke, so injector training and an emergency plan matter.

Where does JUVÉDERM® go as it wears off?

FDA approval documents describe JUVÉDERM® gels as biodegradable, and the VOLLURE® XC review states that the gel degrades through hydrolysis in the body. As the material breaks down, its volume effect diminishes. Normal wear-off is gradual degradation in tissue; migration appears separately in FDA documents as a reported adverse event.

How often are JUVÉDERM® injections repeated?

FDA study schedules varied by product. Optional touch-ups commonly occurred about 30 days after the first injection; repeat treatment was offered at 6 months for SKINVIVE™ and between 12 and 18 months in the VOLLURE® XC fold study, depending on return to baseline. A clinician should set the interval after examining the treated area.

How long does JUVÉDERM® Voluma last?

JUVÉDERM® VOLUMA® XC lasts up to 2 years in the cheeks and up to 1 year in the chin with optimal treatment, according to official US product information. Temple results last more than 1 year. The same gel has area-specific claims, so the treatment site must be included in any duration estimate.

How long does JUVÉDERM® last in nasolabial folds?

JUVÉDERM® VOLLURE® XC can last up to 18 months in nasolabial folds; JUVÉDERM® Ultra Plus XC can last up to 1 year with optimal treatment. In the FDA VOLLURE® study, 59.4% of evaluated folds remained responders at month 18, and 67.8% of subjects assessed for satisfaction were very satisfied at that visit.